Series A
$5.6M
Open roles0
Total raised$5.6M
Team size1-10
Founded · Stage2015 · Series A
We pull jobs from sources most job seekers never check
About the company
What they build and who they serve.
Deep Blue Medical Advances is a Duke University spin-out developing next-generation surgical devices for soft tissue repair and hernia surgery. Its platform centers on the T-Line Mesh, Suture, and Aesthetic Scaffold product lines, purpose-built to prevent suture pull-through and reinforce tissue during closure. Backed by 18 peer-reviewed publications and 21 issued patents, its lockstitch technology has been deployed in more than 20,000 implanted procedures across U.S. hospital systems.
Why it matters
Signals from funding, traction, and product direction.
- The Series A was oversubscribed, per statements from CEO Bill Perry. No backers were named in the press release.
- The round coincided with the promotion of Lou Fuqua, previously Senior Vice President, to Chief Operating Officer, overseeing quality, regulatory affairs, product development, and manufacturing.
- Deep Blue cites 18 peer-reviewed publications, 21 issued patents, and more than 20,000 patented lockstitches and extensions implanted over five years, with multi-center long-term follow-up data.
- Deep Blue Medical Advances is a Duke University spin-out founded in 2014 by Duke plastic surgeon Howard Levinson, MD (per Duke OTC and NC Biotech directory).
Funding history
Rounds and investors over time, newest first.
In the news
Press, announcements, and coverage about this company.
Focus areas
Series AHealthtechMedical Devices
No open roles on the board yet
We do not have indexed listings for Deep Blue Medical right now. Roles may still be open on the company site—we will add them here when they appear in our feed.
Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job posts